Next Generation Sequencing Company
Next Generation Sequencing Company
Psomagen, Inc., previously named Macrogen Corp. in the U.S., was founded in 2004 as a subsidiary from Macrogen, Inc. of S. Korea. Macrogen, Inc. was established in 1997 and in its first year, the South Korean Ministry of Science and Technology selected the company to participate in a leading technology product on gene transplant and gene targeting. Since then, Macrogen has remained on the cutting edge of biotechnology.
In its early years of operation, Macrogen continued to work with the South Korean government, participating in gene transplants for the Ministry of Commerce, Industry and Energy and developing an anti-aging drug with the Ministry of Health and Welfare.
1997 Macrogen Inc. founded
In 2000, Macrogen was the first bio venture company listed on KOSDAQ, a trading board of Korea Exchange in South Korea. The company was growing quickly. That year, it established the DNA Chip Support Center, which focused on research and development in the genomic analysis industry, as well as the Life Science Institute and Bioinformatics Institute.
Macrogen also became one of the first companies in the world to decode the genome of the microorganism Zymomonas, a critical element used in the production of ethanol. The sequence was later listed in the National Center for Biotechnology Information, and Macrogen partnered with Changhae Ethanol Co., Ltd. in 2006 to commercialize the Zymomonas strain for ethanol production.
The early 2000s brought more success for the company. Macrogen, in 2001, was the first Korean company to clone a mouse. In 2003, the company helped decode the genome information of Corynebacterium. It then developed a genome analysis chip that could be used to diagnose hereditary chromosome disorders. The Korea Food and Drug Administration approved its genome analysis chip in 2006, and the chip has since been honored at the Health Industry Technology Exhibition.
Macrogen established its headquarters in the U.S. in Maryland in 2004 as Macrogen Corp. In that year, it partnered with Applied Biosystems for a DNA chip project, and launched a new Sanger sequencing service. The global brand Macrogen continued to expand into Japan and European countries as the U.S. branch grew locally. In 2010, Macrogen Corp. created Axeq Technologies, which served as a sales and marketing function for Next Generation Sequencing.
Macrogen Corp. opened a New York office in 2011, and a Massachusetts office the following year. In 2012, it established the Macrogen Clinical Laboratory. It also became CLIA-certified for whole exome sequencing (WES) and whole genome sequencing (WGS) and acquired HiSeqX and HiSeq2500 in order to launch NGS services for research and clinical purposes. The clinical sequencing service is licensed in 49 states and two U.S. territories. In 2016, Macrogen Corp., Axeq Technologies, and Macrogen Clinical Lab consolidated under Macrogen Corp. The following year, Macrogen Corp. then became CAP-accredited.
Macrogen Corp. has partnered with researchers and clinicians in such institutions as Johns Hopkins University, the National Institutes of Health, Stanford University, and the University of Virginia. It has also collaborated with NRGene, a genomic data company. It has participated in large medical projects such as TOPMed, TEDDY project, Parkinson’s Disease project, and others.
Macrogen Corp. in the U.S. announced its new company name Psomagen in 2019. The name represents the company’s focus on mind, body, and genomics. The “P” comes from the word psyche, “soma” is the Greek word for body, and “gen” is short for gene. In its next phase, Psomagen aims to link genotypic and phenotypic big data to contribute to the health of humanity.
As reflected in the new name, Psomagen, Inc. has focused on creating personalized genome services and implementing sequencing technologies at an early stage in the recent years.
Psomagen is improving its research and development in order to bring genetic information to the personal level. By perfecting its analysis of genes and genomes, its services are better able to recognize the unique differences between patients’ genes, environments, and lifestyles. The research allows Psomagen to generate the data that would assist in predicting the risk of disease, as well as diagnosing and suggesting treatments for individuals.
To support the research and clinical side of personalized medicine, Psomagen’s whole genome and whole exome sequencing processes underwent a rigorous certification process through CLIA (Clinical Laboratory Improvement Amendments) and (CAP) College of American Pathologists. CLIA is a U.S. certification standard coordinated by the Centers for Medicare & Medicaid Services (CMS). The process authenticates the accuracy and reliability of clinical sequencing for the purpose of diagnostics, prevention, and treatment of diseases. The CMS reviews the credentials of laboratory personnel, and it ensures the conditions of the facility are monitored and recorded 24/7. The CAP program inspects the quality and consistency of laboratories, and Psomagen met the highest standards of the inspection process. Psomagen is also HIPAA-compliant.
The global company continues to be at the forefront of genetic and genomic analyses. It researches precision medicine and biotechnology solutions with more than 18,000 research clients in 153 countries around the world.
Inquire About Our Services